Lilly shifts to "FIPNet" to improve productivity and access to assets
This article was originally published in Scrip
Executive Summary
Lilly is transforming itself from a fully integrated pharmaceutical company (FIPCo) to a fully integrated pharmaceutical network (FIPNet) as part of an effort to improve productivity, access to assets and risk management and enhance learning opportunities worldwide.